drugset

drugset / Trial / NCT07238647

A Trial of HRS-5817 in Obese Participants

NCT07238647 ↗

Phase 0 Active not recruiting 40 enrolled Atridia Pty Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess safety, PK, Pharmacodynamic and immunogenicity profile of a single dose of HRS-5817 in obese participants

Timeline

Start: 2026-01-05
Primary completion: 2027-01-30
Completion: 2027-01-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HRS-5817	Unknown	—	Subcutaneous

Indications